Advertisement Pharmaceutical Business review - Page 52 of 5292 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 5, 2026

Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US

Bayer has announced plans to invest $2.2bn in a new pharmaceutical manufacturing facility in Ohio, US.

Continue
Illustration of New Albany International Business Park. Credit: Bayer AG.
October 5, 2026

FDA approves expanded indication for Lilly’s Jaypirca

Both CLL and SLL are slow-growing non-Hodgkin lymphomas that originate in lymphocytes. Credit: Saiful52/Shutterstock.com.
October 1, 2026

BioMarin and Profluent partner on AI-designed enzyme therapies

BioMarin will screen and evaluate the computational outputs, with the objective of advancing selected candidates into preclinical testing. Credit: agustin.photo / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Bristol Myers Squibb secures expanded US approval for Camzyos
  2. OBIO marks $704m funding milestone for Canadian health tech ventures
  3. Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
  4. Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma
  5. AstraZeneca to invest $2bn in Summit for ADC combination therapies

PRESS RELEASES

Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
Pharmaceutical Business Review
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography